Abstract
DNA-spermidine (DA-51), which has been originally developed by Dr. Sekiguchi et al. as a protective agent against radiation-induced leukopenia, was submitted to clinical trial by the double blind test. The protective effect against radiation-induced leukopenia and side effect of DA-51 were compared with those of Inosine, selected as a control agent, on breast cancer cases receiving prophylactic irradiation. Daily dose of 2700 mg of DA-51 and 1800 mg of Inosine were administered orally during a 5 week period of irradiation. The differences between the white blood cell counts, the thrombocyte counts and the percentages of lymphocytes in the DA-51 and the Inosine treated groups were assessed at 1, 3 and 5 weeks by x/sup 2/ and T tests, and the following results are obtained: No significant difference in white blood cell or thrombocyte counts was demonstrated at 1, 3 or 5 weeks between the two groups. The only significant difference noted was in the percentage of lymphocyte at 5 weeks, and the thrombocyte counts at 3 weeks. DNA-spermidine is considered to be an effective drug against radiation-induced leukopenia, comparable to Inosine and without noticeable side effects.
Tsuya, A;
Kaneta, K;
Okawa, T;
Nakama, M;
[1]
Watari, T
- Japanese Foundation for Cancer Research, Tokyo. Hospital
Citation Formats
Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T.
Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation.
Japan: N. p.,
1976.
Web.
Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, & Watari, T.
Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation.
Japan.
Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T.
1976.
"Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation."
Japan.
@misc{etde_7210089,
title = {Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation}
author = {Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T}
abstractNote = {DNA-spermidine (DA-51), which has been originally developed by Dr. Sekiguchi et al. as a protective agent against radiation-induced leukopenia, was submitted to clinical trial by the double blind test. The protective effect against radiation-induced leukopenia and side effect of DA-51 were compared with those of Inosine, selected as a control agent, on breast cancer cases receiving prophylactic irradiation. Daily dose of 2700 mg of DA-51 and 1800 mg of Inosine were administered orally during a 5 week period of irradiation. The differences between the white blood cell counts, the thrombocyte counts and the percentages of lymphocytes in the DA-51 and the Inosine treated groups were assessed at 1, 3 and 5 weeks by x/sup 2/ and T tests, and the following results are obtained: No significant difference in white blood cell or thrombocyte counts was demonstrated at 1, 3 or 5 weeks between the two groups. The only significant difference noted was in the percentage of lymphocyte at 5 weeks, and the thrombocyte counts at 3 weeks. DNA-spermidine is considered to be an effective drug against radiation-induced leukopenia, comparable to Inosine and without noticeable side effects.}
journal = []
volume = {36:8}
journal type = {AC}
place = {Japan}
year = {1976}
month = {Aug}
}
title = {Protective effect of DNA-spermidine (DA-51) against radiation-induced leukopenia. A study on breast cancer patients receiving postoperative prophylactic irradiation}
author = {Tsuya, A, Kaneta, K, Okawa, T, Nakama, M, and Watari, T}
abstractNote = {DNA-spermidine (DA-51), which has been originally developed by Dr. Sekiguchi et al. as a protective agent against radiation-induced leukopenia, was submitted to clinical trial by the double blind test. The protective effect against radiation-induced leukopenia and side effect of DA-51 were compared with those of Inosine, selected as a control agent, on breast cancer cases receiving prophylactic irradiation. Daily dose of 2700 mg of DA-51 and 1800 mg of Inosine were administered orally during a 5 week period of irradiation. The differences between the white blood cell counts, the thrombocyte counts and the percentages of lymphocytes in the DA-51 and the Inosine treated groups were assessed at 1, 3 and 5 weeks by x/sup 2/ and T tests, and the following results are obtained: No significant difference in white blood cell or thrombocyte counts was demonstrated at 1, 3 or 5 weeks between the two groups. The only significant difference noted was in the percentage of lymphocyte at 5 weeks, and the thrombocyte counts at 3 weeks. DNA-spermidine is considered to be an effective drug against radiation-induced leukopenia, comparable to Inosine and without noticeable side effects.}
journal = []
volume = {36:8}
journal type = {AC}
place = {Japan}
year = {1976}
month = {Aug}
}